Novel Antipsychotic Drugs

Editor

Herbert Y. Meltzer, M.D.
Douglas D. Bond Professor of Psychiatry
Case Western Reserve University
School of Medicine
Cleveland, Ohio

Raven Press New York
Contents

Clozapine Type Atypical Antipsychotic Drugs

Contributors ix
Preface xv
1. The Mechanism of Action of Clozapine in Relation to Its Clinical Advantages 1
   Herbert Y. Meltzer
2. Org 5222: Preliminary Clinical Results 15
   J. M. Ad Sitsen and Maria C. Vrijmoed-de Vries
3. Amperozide and Some Other Atypical Compounds with Antipsychotic Effect 19
   Erik G. Christensson
4. Clozapine: Pattern of Efficacy in Treatment-Resistant Schizophrenia 33
   Herbert Y. Meltzer
5. Amperozide in the Treatment of Schizophrenic Patients: A Preliminary Report 47
   Anders Björk, I. Bergman, and G. Gustavsson

Substituted Benzamides

6. Comparison of the Effects of Different Substituted Benzamides on Dopamine Receptor Function in the Rat 59
   Sven O. Ögren and Håkan Hall
7. Remoxipride and Raclopride: Pharmacological Background and Clinical Outcome 67
CONTENTS

Dopamine Agonists

8. Effects of PD 128483, A Novel Dopamine Autoreceptor Agonist, in Preclinical Antipsychotic Tests .............. 79
   Thomas G. Heffner, B. Caprathe, M. Davis, J. Jaen, L. Meltzer, T. Pugsley, and L. Wise

9. Novel Dopamine Autoreceptor Agonists B-HT 920 and EMD 49980 in the Treatment of Patients with Schizophrenia ........................................ 91
   Klaus Wiedemann, Jürgen-Christian Krieg, Albrecht Loycke, and Florian Holsboer

10. Efficacy and Tolerability of SDZ HDC 912, A Partial Dopamine D₂ Agonist, in the Treatment of Schizophrenia .................................................. 99
    Dieter Naber, C. Gaussares, J. M. Moeglen, L. Tremmel, Paul E. Bailey, and the SDZ HDC 912 Collaborative Study Group

11. The Status of “Second Generation” Selective D₁ Dopamine Receptor Antagonists as Putative Atypical Antipsychotics Agents .................................... 109
    John L. Waddington and Siobhan A. Daly

12. Towards the Understanding of the Neuroanatomical Substrate of Schizophrenia: The Contribution of Savoxepine ......................... 117
    Serge F. Bischoff

13. The Dopamine D₃ Receptor as a Target for Antipsychotics .......................................................... 135
    Jean-Charles Schwartz, Pierre Sokoloff, Bruno Giros, Maria Pascale Martres, and M. L. Bouthenet

14. Receptor Selectivities of Atypical Neuroleptics ........ 145
    Philip Seeman

Other Approaches

15. Glutamatergic Mechanisms in Neuropsychiatry ........... 155
    John W. Olney

    Carol A. Tamminga, N. Cascella, T. D. Fakouhi, and R. L. Herting
CONTENTS

17. Glycine in the Treatment of Schizophrenia: Theory and Preliminary Results ................................................. 179
   Steven G. Potkin, Jerome Costa, Swati Roy, John Sramek, Yi Jin, and Bala Gulasekaram

   Duncan P. Taylor and R. Francis Schlemmer, Jr.

19. Clinical Efficacy of Sigma Antagonists in Schizophrenia ................................................................. 203
   Richard L. Borison, Ananda P. Pathiraja, and Bruce I. Diamond

20. Antipsychotic Potential of 5-HT\textsubscript{3} Antagonists: Preclinical Data .................................................. 211
   Michael G. Palfreyman, Stephen M. Sorensen, Bruce M. Baron, Teresa M. Humphreys, Paul C. Moser, and Mark W. Dudley

21. The Effects of a Novel 5-HT\textsubscript{3} Antagonist, Ondansetron, in Schizophrenia: Results From Uncontrolled Trials .... 225
   Joseph DeVeaugh-Geiss, Sharon McBain, Peter G. Cooksey, and Joanne M. Bell

22. Clinical Overview of Risperidone ........................................ 233
   Richard L. Borison, Bruce I. Diamond, Ananda P. Pathiraja, and Richard C. Meibach

23. What Makes a Neuroleptic Atypical? ............................... 241
   Daniel E. Casey

Subject Index ................................................................. 253